The programmed death (PD)-1 molecule and its ligands (PD-L1 and PD-L2), negative regulatory members of the B7 family, play an important role in peripheral tolerance. Previous studies have demonstrated that PD-1 is up-regulated on T cells following TCR-mediated activation; however, little is known regarding PD-1 and Ag-independent, cytokine-induced T cell activation. The common ␥-chain (␥c) cytokines IL-2, IL-7, IL-15, and IL-21, which play an important role in peripheral T cell expansion and survival, were found to up-regulate PD-1 and, with the exception of IL-21, PD-L1 on purified T cells in vitro. This effect was most prominent on memory T cells. Furthermore, these cytokines induced, indirectly, the expression of PD-L1 and PD-L2 on monocytes/macrophages in PBMC. The in vivo correlate of these observations was confirmed on PBMC isolated from HIV-infected individuals receiving IL-2 immunotherapy. Exposure of ␥c cytokine pretreated T cells to PD-1 ligand-IgG had no effect on STAT5 activation, T cell proliferation, or survival driven by ␥c cytokines. However, PD-1 ligand-IgG dramatically inhibited anti-CD3/ CD28-driven proliferation and Lck activation. Furthermore, following restimulation with anti-CD3/CD28, cytokine secretion by both ␥c cytokine and anti-CD3/CD28 pretreated T cells was suppressed. These data suggest that ␥c cytokine-induced PD-1 does not interfere with cytokine-driven peripheral T cell expansion/survival, but may act to suppress certain effector functions of cytokine-stimulated cells upon TCR engagement, thereby minimizing immune-mediated damage to the host.
5-day cycle) were collected/frozen on day 1 before the first IL-2 administration and day 5 before the last two doses. All patients received IL-2 while also receiving effective antiretroviral therapy, leading to a suppression of viral load to Ͻ50 copies/ml.
Cellular stimulation
Freshly isolated PBMC were cultured at 10 6 /ml in media (RPMI 1640 plus 1 mM HEPES buffer and penicillin/streptomycin with 10% human AB serum) alone or with IL-1␤ (5-100 ng/ml), IL-2 (5-200 IU/ml), IL-4 (5-100 ng/ml), IL-6 (5-100 ng/ml), IL-7 (5-100 ng/ml), IL-8 (5-100 ng/ml), IL-10 (5-100 ng/ml), IL-12 (25-200 ng/ml), IL-15 (5-100 ng/ml), IL-18 (5-100 ng/ml), IL-21 (5-200 ng/ml), TGF-␤ (5-100 ng/ml), IFN-␥ (5-100 ng/ml), TNF-␣ (2-50 ng/ml), or anti-human CD3 (5 g/ml) plus antihuman CD28 (2 g/ml) (BD Pharmingen). All cytokines were purchased from the National Cancer Institute Biological Resource Branch Preclinical Repository (Frederick, MD) or R&D Systems. Cells were monitored for PD-1 expression during a 10 -16-day period. For all subsequent analyses, unless otherwise indicated, PBMC, purified total T cells, or CD45RA Ϫ (memory) T cells were cultured in media plus IL-2 (200 IU/ml), IL-7 (25 ng/ml), IL-15 (100 ng/ml), IL-21 (100 ng/ml), or anti-CD3/CD28 (as above).
Phenotyping
PD-1 and PD-L expression and naive/memory subset phenotypes were assessed using anti-human PD-1 (clone MIH4), PD-L1 (clone MIH1; eBioscience), or PD-L2 (clone MIH18; eBioscience), CD45RA, CD62L, CD3, CD4, and CD8. PBMC were stained for CD3, CD19, CD14, and PD-L1 or PD-L2. Frozen PBMC obtained from HIV-positive subjects receiving IL-2 in vivo were thawed (all time points per patient were assayed at the same time) and stained for PD-1, PD-L1, PD-L2, CD3, CD4, CD8, CD19, CD14, Ki67, and HLA-DR. All mAbs were purchased from BD Pharmingen unless otherwise indicated.
STAT5 and Lck activation
Purified human T cells were prestimulated with IL-2 or anti-CD3/CD28 for 6 days. Harvested cells were restimulated with IL-2 plus tosylactivated beads (Invitrogen/Dynal) coated with hIgG or PD-L2 hIgG (2 g/10 7 beads) or with beads coated with anti-CD3 (4 g/10 7 beads)/ anti-CD28 (2 g/10 7 beads) or isotype plus PD-L2 or hIgG (3:1 beadto-cell ratio). Cells were stimulated for 15 (Lck) or 45 (STAT5) min at 37°C and then stained with phospho-specific Y505 Lck (BD Pharmingen, clone 4/LCK-Y505), phospho-specific Y694 STAT-5 (BD Pharmingen clone 47), PD-1 (BD Pharmingen, clone MIH4), and CD8 (BD Pharmingen) using eBioscience's Fix/Perm solution per the manufacturer's instructions.
Functional assays
Proliferation. Freshly isolated, purified T cells, or PBMC (candida) were plated (10 5 /well) in 96-well plates either 1) coated with isotype hIgG or hPD-L1-IgG or hPD-L2-IgG chimeric proteins (5 g/ml, R&D Systems) or 2) in the presence of neutralizing anti-PD-L1 Ab (5 g/ml; eBioscience). Cells were then stimulated with plate-bound anti-CD3 (0.2 g/ml)/anti-CD28 (0.4 g/ml), Candida albicans (5 g/ml), or with ␥c cytokines. Proliferation was assessed by 16-h [ 3 H]thymidine uptake at day 6 poststimulation. Cytokine production and apoptosis. Purified T cells received an initial stimulation with ␥c cytokines or anti-CD3/CD28 (5/2 g/ml) for 5-8 days. Cells were washed, restimulated with plate-bound anti-CD3/CD28 (0.2/0.4 g/ml) plus hIgG, PD-L1-hIgG, or PD-L2-hIgG (5 g/ml) and tested in parallel for annexin V or cytokine production. For cytokine production, brefeldin A (GolgiPlug; BD Pharmingen) was added 2 h after restimulation, and 4 h later cells were stained for PD-1, CD8, and intracellular IL-2 and IFN-␥ as per the manufacturer's recommendations. Apoptosis was assessed at 6 h after restimulation by staining for PD-1, annexin V (BD Pharmingen), CD4, and CD8. In certain apoptosis experiments, prestimulated T cells were exposed to PD-L1 or PD-L2 IgG in the absence of anti-CD3; however, results are not shown but were similar to those reported below.
Statistical analyses
Paired Student's t test and Spearman's nonparametric correlation were used for statistical analyses.
Results

In vitro cytokine-mediated induction of PD-1 expression
Induction of PD-1 expression has been previously described only under conditions of TCR stimulation. In the present study, we investigated whether cytokine-mediated immune activation can contribute to PD-1 expression. PBMC were stimulated with a variety of cytokines and T cells were monitored for PD-1 expression. Of those cytokines tested, IL-2, IL-7, IL-12, IL-15, and IL-21 induced significant levels of PD-1 expression above background (untreated cells), whereas proinflammatory (IL-1␤ and TNF-␣; IL-6, IL-8 data not shown), immunosuppressive (TGF-␤; IL-10, data not shown), and certain immunoregulatory (IL-4 and IFN-␥; IL-18, data not shown) cytokines had no significant effect (Fig. 1A) .
While IL-12 induced PD-1 on CD8 ϩ T cells in the context of PBMC ( Fig. 1A and supplemental Fig. 1) , 3 only the ␥c cytokines IL-2, IL-7, IL-15, and IL-21 were found to directly induce PD-1 expression on purified T cells (Fig. 1, B-E) . ␥c cytokines increased the frequency of PD-1 ϩ cells (Fig. 1C) and modestly increased the PD-1 mean fluorescence intensity (MFI) (Fig. 1D ) on both CD4 ϩ (IL-21 had no effect on MFI) and CD8 ϩ T cells. A significant difference in cytokine-induced PD-1 expression between CD4 ϩ and CD8 ϩ T cells was seen only with IL-21 treatment (Fig. 1, C  and D) . ␥c cytokines induced PD-1 expression on purified T cells more slowly than did anti-CD3/CD28 stimulation, but effects were long lasting and increased over time, with the exception of IL-21 (cells did not survive beyond 6 -8 days) (Fig. 1E ϩ CD62L Ϫ ) frequencies were also elevated, but few events were present in this gate (Fig. 2, A and B) . While there were significant differences in the percentages of PD-1 ϩ CD8 ϩ vs CD4 ϩ T cells, there were no significant differences in the response (fold induction vs untreated) to any stimulation condition in any subset. The frequency of PD-1 high T EM cells was increased by IL-2, IL-15, and IL-21, whereas anti-CD3/CD28 stimulation induced PD-1 high expression in all T cell subsets (supplemental Fig.  2A ). Of note, the T Eff population had a higher frequency of PD-1 high cells than did other subsets under both untreated and cytokine-treated conditions (supplemental Fig. 2A ). Moderate cytokine 3 The online version of this article contains supplemental material. concentrations (6 ng/ml) were effective in up-regulating PD-1 on purified memory (CD45RA Ϫ ) T cells; however, IL-2 and IL-15 were most effective at high concentrations (Fig. 2C ).
In vitro cytokine-mediated induction of PD-1 ligand expression
The functional consequences of PD-1 expression on T cells clearly rely on the interaction of these cells with PD-1 ligandexpressing cells. PD-L2 (B7-DC) expression is largely restricted to dendritic cells and activated macrophages, whereas PD-L1 (B7-H1) is expressed more promiscuously and can be found on a variety of hematopoietic and nonhematopoietic cells, particularly in the tissue (32, 33) . While PD-L1 and PD-L2 have been shown to be up-regulated on both professional and nonprofessional APC upon stimulation with TLR ligands and certain cytokines (32, 33) , such as IFN-␥, the effects of ␥c cytokines on PD-1 ligand expression have not been reported. In the context of total PBMC, ␥c cytokines increased the frequency and, with the exception of IL-21, the MFI of PD-L1 . 3C ) and frequency (data not shown) were modestly, but significantly, elevated by all ␥c cytokines except IL-21. However, PD-L1 expression (MFI) on T cells remained significantly lower than on M/M under all conditions (Fig. 3C) . The frequency, but not the MFI (data not shown), of PD-L2 ϩ M/M was increased by IL-2, IL-15, and IL-21 (Fig. 3B) ; no PD-L2 was observed on T or B cells (data not shown). All ␥c cytokines, with the exception of IL-21, induced PD-L1 expression on purified T cells, and IL-21 was the only ␥c cytokine to up-regulate PD-L1 on B (CD19 ϩ ) cells in PBMC (Fig. 3D) . Of interest, treatment of purified T cells with IL-2, IL-7, and IL-15 increased the frequency of PD-L1 on all memory/effector and naive T cell subsets (supplemental Fig. 2B ).
In vivo IL-2-mediated induction of PD-1 and PD-1 ligand expression
To determine whether cytokines can modulate the PD-1 axis in vivo, PD-1 and PD-L expression was assessed on PBMC isolated from HIV-positive subjects (n ϭ 5; HIV viral load Ͻ50) before and during (day 5) administration of IL-2 immunotherapy. Following IL-2 administration, the frequency of activated (HLA-DR ϩ ) PD-1 ϩ CD4 ϩ and CD8 ϩ T cells, and the MFI of PD-1ϩ CD8 ϩ T cells, was significantly elevated (Fig. 4, A and B) . Furthermore, the frequency of M/M and T cells expressing PD-L1 (Fig. 4C, left) and of M/M expressing PD-L2 (Fig. 4C, right) was also increased. Of note, IL-2 therapy was associated with elevated frequencies of PD-1 ϩ T cells expressing the proliferation Ag Ki67 (Fig. 4D) , suggesting that IL-2-mediated induction of PD-1 or its ligands did not interfere with the ability of PD-1 ϩ cells to proliferate in vivo in response to this cytokine.
Functional consequences of ␥c cytokine-mediated modulation of the PD-1 axis
Several of these ␥c cytokines are currently being used, or are being considered, as modalities for immunotherapy (16, 23, 25) or as adjuvants in the context of vaccination (34 -36) . It is therefore important to determine the potential role of the PD-1 axis in modulating the activity and/or survival of ␥c cytokine-stimulated lymphocytes. Engagement of PD-1 has been shown to inhibit TCR-stimulated T cell proliferation and effector function (1, 6, 37, 38) and has also been associated with increased apoptosis (8 -10); any of these effects could have negative consequences on cytokinemediated T cell expansion and survival. Proliferation was assessed in purified T cells stimulated with ␥c cytokines or TCR stimuli (anti-CD3/CD28 and recall Ag (C. albicans in PBMC)) in the presence of hIgG control, PD-L1-hIgG, or PD-L2 hIgG (Fig. 5A ) or in the presence of neutralizing anti-PD-L1 Ab (Fig. 5B) . IL-2, IL-7, and IL-15 induced significant proliferation of purified T cells; IL-21-treated cells did not survive well at day 6 and thus did not incorporate thymidine (Fig. 5A) . The presence of either PD-L1 IgG or PD-L2 IgG at the time of initial stimulation significantly suppressed anti-CD3/CD28, and the presence of PD-L1 IgG suppressed Candida-stimulated proliferation; however, neither PD-L1 nor PD-L2 IgG significantly reduced ␥c cytokine-induced proliferation (Fig. 5A ). In addition, we investigated the role of endogenous T cell-associated PD-L1 in proliferation by conducting assays using purified T cells in the presence of neutralizing anti-PD-L1 Ab. Anti-PD-L1 Ab had no significant effect on the ability of purified T cells to proliferate in response to either immobilized anti-CD3/CD28 or ␥c cytokines (Fig. 5B) , suggesting that endogenous T cell-associated PD-L1 does not significantly inhibit proliferation under these in vitro conditions.
To verify that PD-1 engagement does not inhibit ␥c cytokineinduced intracellular signaling events, STAT5 activation (␥c cytokine signaling; IL-2) and Lck activation (TCR complex-signaling; anti-CD3-CD28) was determined in the presence PD-L2 IgG. Purified T cells were pre-stimulated with IL-2 or anti-CD3/CD28 (6 days) to induce PD-1 expression. Cells were then exposed to hIgG or PD-L2 IgG at the time of secondary stimulation with IL-2 or anti-CD3/CD28 and stained for active (phosphorylated) Lck or STAT5. Whether PD-1 was initially induced by IL-2 or by anti-CD3/CD28 pre-treatment, engagement of PD-1 by PD-L2 IgG at the time of secondary stimulation inhibited signaling mediated by the TCR complex ( Fig. 5C , left; Lck) but not by IL-2 ( Fig. 5C,  right; STAT5) .
Having determined that PD-1 engagement does not directly interfere with ␥c cytokine-mediated proliferation or signaling events, the effects of PD-1 ligation on the survival and function ␥c cytokine and anti-CD3/CD28 pretreated T cells following restimulation via TCR was evaluated. Purified ␥c cytokine and anti-CD3/ CD28 prestimulated T cells were harvested at time points of strong PD-1 expression (6 -8 days poststimulation), washed, and then restimulated with anti-CD3/CD28 in the presence of hIgG (control), PD-L1 IgG, or PD-L2 IgG. Cells were then tested in parallel for cytokine production (intracellular cytokine (ICC)) and apoptosis (annexin V) after 5-6 h.
␥c cytokine pretreated T cells produced high levels of IL-2 and IFN-␥ following restimulation with anti-CD3/CD28 in the absence of PD-1 ligands (hIgG control) (Fig. 6) . The frequency of IL-2 ϩ , IFN-␥ ϩ , and IL-2 ϩ /IFN-␥ ϩ T cells following restimulation in the presence of hIgG was significantly higher in ␥c cytokine pretreated cells compared with cells not receiving prior stimulation and with anti-CD3/CD28 prestimulated cells ( p ϭ 0.04 -0.0004; not shown) (Fig. 6B) . However, the presence of either PD-L1 or PD-L2 IgG during restimulation dramatically reduced the frequency of IFN-␥ ϩ (Fig. 6B, left) , IL-2 ϩ /IFN-␥ ϩ (Fig. 6B, middle) , and IL-2 ϩ (Fig. 6B, right) populations in T cells prestimulated with either ␥c cytokines or anti-CD3/CD28. There were no significant differences between PD-L1 and PD-L2 IgG for this effect.
PD-1 engagement has been described to induce apoptosis in certain studies, while other studies find PD-1 to simply be a marker for susceptibility to apoptosis (6, 8 -11) . To investigate the impact of cytokine-induced PD-1 on apoptosis, pretreated (as above) T cells were washed, restimulated with anti-CD3/CD28 in the presence of hIgG, PD-L1, or PD-L2 IgG, and apoptosis (surface annexin V ϩ ) was assessed in the PD-1 high (MFI Ͼ 100), PD-1 mid (Fig.  7A ). When restimulated with anti-CD3/CD28 in the absence of the PD-1 ligand (control hIgG), the frequency of apoptosis differed significantly based on the level of PD-1 expression (PD-1 high Ͼ PD-1 mid Ͼ PD-1 Ϫ subsets) under all conditions tested (Fig. 7B) ; similar results were observed in cells not receiving a secondary TCR stimulation (data not shown). ␥c cytokine pretreatment resulted in a small, but significant, reduction in apoptosis within the PD-1 mid population (Fig. 7C, left) compared with anti-CD3/ CD28 pretreatment or no prior treatment; only IL-7 reduced apoptosis in the PD-1 high (Fig. 7C, right) T cell population. Of note, the reduction of apoptosis in PD-1 ϩ populations by cytokine pretreatment was maintained even in the presence of PD-L1 or PD-L2 IgG (Fig. 7C ).
Discussion
␥c cytokines play an important role in peripheral T cell expansion, function, and survival, and therefore several of these cytokines are currently being administered in vivo as immunotherapy in certain diseases (16, 25) , as well as adjuvants in vaccination. However, ␥c cytokine administration and HPE under lymphopenic conditions can be associated with prolonged or excessive peripheral T cell expansion/activation, increasing the possibility for immune-mediated damage to the host (26 -31) . The PD-1 axis has been shown to play an important role in controlling the potentially harmful activity of peripheral T cells that are reactive to self Ags and persistent foreign Ags (2, 6, 13) ; however, the role of PD-1 in maintaining tolerance during cytokine-driven T cell activation/expansion has not been investigated. The present study demonstrates that the ␥c cytokines IL-2, IL-7, IL-15, and IL-21 directly induce the PD-1 axis in purified T cells and PBMC of healthy subjects in vitro and in PBMC of HIV-infected subjects receiving IL-2 immunotherapy in vivo. The results of in vitro functional assays suggest that engagement of ␥c cytokine-induced PD-1 does not suppress ␥c cytokine-mediated signal transduction, T cell expansion, or enhancement of function and survival, but does significantly inhibit certain effector functions (cytokine production) of cytokine-stimulated T cells upon subsequent TCR triggering. This is the first report, to our knowledge, of ␥c cytokine-mediated up-regulation of the PD-1 axis. Although the list of cytokines screened in the present study for the ability to modulate PD-1 was not exhaustive, the ability to induce PD-1 expression on purified T cells was limited to certain ␥c cytokines (IL-2, IL-7, IL-15, and IL-21; Fig. 1 ). While all these cytokines play a role in promoting T cell expansion, survival, or function during normal immune responses, IL-7 and IL-15 play a critical role in HPE (20, 22, 27, 39 -47) . The induction of PD-1 expression in vitro by ␥c cytokines was restricted to memory (T EM and T CM ) and effector T cells (Fig.  2) . In this regard, it has been reported that memory, but not naive, T cell populations can undergo expansion that is cytokine driven and TCR-MHC-independent, at least in mice (39, 40, 45) . Of interest, naive T cell subsets did respond to IL-2, IL-7, and IL-15, as did memory/effector subsets, by up-regulating PD-L1 (supplemental Fig. 2B ). IL-2, IL-7, and IL-15 increased both the frequency and, to a lesser extent, the MFI of PD-L1 ϩ T cells; however, PD-L1 remained at much lower levels (MFI) than those seen on M/M (Fig. 3) . We found no significant inhibitory role of T cell-associated PD-L1 in purified T cell cultures (Fig.  5) ; however, in our in vitro conditions PD-L1 ϩ T cells are not presenting Ag. In studies demonstrating suppression via PD-L1-B7.1 (48, 49) or PD-L1-PD-1 (1, 6, 7), TCR is co-engaged either by beads or alloreactive T cells. Only IL-21 significantly induced PD-L1 on B cells (Fig. 3) , consistent with its effect on B cell activation/differentiation (44, 50) . PD-L1 and, to a lesser extent, PD-L2 expression on M/M in PBMC in vitro (Fig. 3 ) and in vivo (HIV-positive subjects receiving IL-2 immunotherapy; Fig. 4 ) was dramatically up-regulated by ␥c cytokines. ␥c cytokines did not induce PD-1 ligand expression on purified M/M in vitro, and the effect on M/M in PBMC was found to be largely IFN-␥-dependent (data not shown).
The lack of an inhibitory effect of PD-1 engagement on ␥c cytokine-mediated signaling or downstream functional events in vitro (Fig. 5) is not surprising based on our understanding of PD-1-mediated immunosuppression. Our data are consistent with previous studies demonstrating that the inhibitory effects of PD-1 engagement may require TCR-triggered SHP-2 recruitment to the cytoplasmic tail of PD-1 and that PD-1 ligation by itself does not generate a suppressive signal (7) . Furthermore, PD-1 inhibitory effects appear to require that the TCR and PD-1 signals be delivered in both temporal and physical proximity (7). Our observation that PD-L1 Ig or anti-PD-L1 neutralizing Ab does not alter cytokine-driven proliferation data is supported by the observation of increased proliferation (Ki67 expression) in PD-1 ϩ T cells following in vivo administration of IL-2 to HIV-infected subjects (Fig.  4D) . Of interest, IL-7 and IL-15 have previously been found to rescue proliferation of T cells stimulated with anti-CD3 in the presence of PD-L1 (51), suggesting that PD-1 engagement does not inhibit proliferation driven by these cytokines even if TCR triggering is contributing to the expansion of T cells in vivo. In contrast, ␥c cytokine pretreatment did render TCR-triggered effector function (measured by cytokine (IL-2/IFN-␥) secretion; Fig.  6 ) of T cells sensitive to PD-1-mediated suppression. The ability of PD-1 engagement to induce apoptosis remains controversial (6, 8, 9, 11) . Our data suggest that PD-1 does not mediate apoptosis, even in the context of TCR signaling, but rather that the level of PD-1 expression (MFI) correlates with susceptibility to apoptosis (Fig. 7) . Consistent with the pro-survival effects of these ␥c cytokines (21, 39 -41, 52), pretreatment of T cells with ␥c cytokines, particularly IL-7, moderately reduced apoptosis within the PD-1 ϩ cell populations and this effect was maintained even in the presence of PD-1 ligands. Of note, the protective effects of cytokines on cell death seen in this study were less than those reported by other studies in which cytokines were present during stimulation/ apoptosis assessment. Whether ␥c cytokine-induced PD-1 influences T cell function upon subsequent TCR triggering is particularly relevant in the setting of cytokines administered as immunotherapy or as vaccine adjuvants (14 -25) . While modest (6 ng/ml) concentrations of ␥c cytokines induced PD-1 expression on memory T cells in vitro (Fig. 2) , normal in vivo levels of these cytokines may be insufficient, except perhaps in tissue microenvironments, to induce the PD-1 axis at a functionally relevant level. Furthermore, note that T cell restimulations were conducted using low concentrations of anti-CD3 and anti-CD28 in the presence of considerable concentrations of PD-1 ligands. These in vitro conditions may reflect conditions existing during the interaction between T cells and nonprofessional APC expressing high levels of PD-1 ligands. Thus, our data need not conflict with the use of ␥c cytokines as adjuvants in the context of vaccination or as immunotherapy to enhance Agspecific T cell responses (14 -25) . However, these data may provide some insight into the optimal timing of cytokine administration (and thus PD-1 axis induction) relative to TCR triggering (vaccines or persistent pathogens whose replication can be modulated by treatment) (53, 54) . Furthermore, the inability to detect an improvement of T cell function following ␥c cytokine administration may be influenced by the timing, relative to cytokine administration, of when cells are reexposed to Ag and assayed for function (53, 54) .
In summary, the present study provides evidence that the ␥c cytokines IL-2, IL-7, IL-15, and IL-21, known to play an important role in peripheral T cell activation and/or expansion and survival, up-regulate both PD-1 and its ligands in vitro and in vivo. Of note, the expression of PD-1/PD-1 ligand does not appear to negatively impact the ability of T cells to expand, function, or survive in response to further ␥c cytokine exposure, but does render them susceptible to PD-1 ligand-mediated suppression of TCR-triggered function. It remains to be established whether induction of the PD-1 axis by any of these ␥c cytokines plays a role in maintaining tolerance in vivo under conditions of significant cytokine-driven T cell activation/expansion, such as during immunotherapy and, in some cases, HPE in lymphopenic individuals.
